What Vetranquil 1% Treats: Main Uses and Benefits

Vetranquil 1% (Acepromazine maleate) is commonly used in clinical settings to help manage certain distressing symptoms, offering supportive symptomatic assistance. This medication is utilized for easing symptoms related to heightened physiological activity, especially in tranquilization and pre-anesthetic protocols. It is applied across therapeutic areas where short-term symptomatic assistance is appropriate, including the management of behavioral excitability, the facilitation of pre-anesthetic procedures, and the supportive relief of acute stress-related symptoms, such as vomiting and symptoms related to inflammatory or irritative states.

Therapeutic Use Summary

In situations where patients experience excessive nervousness, restlessness, or highly fractious behavior that creates noticeable interference with safe handling, Vetranquil 1% helps address these symptom clusters. It is also commonly used when short-term symptomatic assistance is needed prior to surgery, contributing to a state of calmness and muscular relaxation. This supportive benefit may assist with the transition into general anesthesia.

---

Quick Fact: Symptom Management in Acute Settings

Symptomatic Use	Primary Benefit
Behavioral Excitability	Supports functional stability during handling and procedures.
Pre-Anesthetic Support	Assists with the transition into general anesthesia.
Motion Sickness	Helps address symptoms that interfere with necessary transportation.

Regulatory References

1. U.S. Food and Drug Administration (FDA) approved label

Eligibility Scope: Official Regulatory Information

Populations for whom use is allowed: Vetranquil 1% (Acepromazine maleate injection) is officially approved for use in dogs, cats, and horses.

Populations for whom use is contraindicated: Use is absolutely contraindicated in animals with acute circulatory conditions, specifically those exhibiting hypotension, hypovolemia, or post-traumatic shock. It is also prohibited in animals with certain blood disorders (e.g., severe anemia) and those exposed to organophosphate poisoning or procaine hydrochloride. Furthermore, federal regulations forbid its use in any animal intended for human consumption.

Condition-Specific Eligibility Restrictions: The official labeling mandates use with caution in animals exhibiting symptoms of cardiac disease or those with a history of liver dysfunction. Caution is similarly required for debilitated or highly stressed patients. Age-related eligibility notes include contraindications for dogs less than three months of age in some regions.

Special Population Status: Safety has not been established during pregnancy and lactation, meaning its use is conditional upon a benefit/risk assessment. Specific breeds, such as Boxers and giant breeds, require special care due to documented physiological sensitivity.

Connection to the overall eligibility profile: Regulatory documents strictly define who can and cannot use the medicine by establishing definitive contraindications tied to the animal's circulatory status and specific toxic exposures. These rules, alongside the mandated caution for organ impairment and the regulatory exclusion for food animals, collectively limit the patient population to those meeting specified health criteria.

Vetranquil 1% (Acepromazine maleate) interacts with several medicinal products and substance classes, as documented in official regulatory labeling.

Formally Documented Interactions

Co-administration is formally contraindicated with Organophosphates (including vermifuges and ectoparasiticides) because phenothiazines potentiate the toxicity of these substances. The combination with Procaine hydrochloride is also prohibited, as Acepromazine may potentiate its activity.

The drug exhibits significant pharmacodynamic potentiation with Centrally Depressant Drugs (such as barbiturates and narcotics) and General Anesthetics, resulting in an additive depressant action. This requires a mandatory reduction in the induction dose of other agents when general anesthesia is performed within the four-to-six hour window following administration. Due to the risk of hypotensive augmentation, the drug potentiates the effects of Blood Pressure Lowering Products. Epinephrine is explicitly prohibited for treating acute hypotension caused by Acepromazine, as it may further depress blood pressure.

A pharmacokinetic interaction note states that Antacids may cause a decrease in gastrointestinal absorption following oral administration.

Population-Specific Interaction Notes

Regulatory documents highlight interaction considerations for specific populations, including the caution required in animals with liver dysfunction (due to the drug's detoxification pathway) and the need for dose reduction in dogs with the ABCB1-1Delta (MDR1) mutation.

How Vetranquil 1% Works

Vetranquil 1% (Acepromazine maleate) exerts its effect by modulating key neurotransmitter signaling pathways in the central and peripheral nervous systems. The drug's activity is rooted in two primary mechanistic domains: antagonism of central dopamine receptors and blockade of peripheral alpha1-adrenergic receptors.

---

Central Dopaminergic Receptor Antagonism

This domain addresses the drug’s primary central inhibitory action. Vetranquil acts as an antagonist at dopamine receptors (D2) within the basal ganglia and limbic system, which effectively modulates signaling activity in neural pathways associated with arousal and emotional reactivity. This mechanism alters activity within central pathways, which shapes the observable central physiological outcome.

---

Peripheral alpha1-Adrenergic Receptor Blockade

The drug targets the alpha1-adrenergic receptors found on vascular smooth muscle, thus interfering with the action of norepinephrine. This action initiates a signaling sequence that suppresses sympathetic vasoconstriction, leading to peripheral vasodilation. This mechanism alters signaling dynamics within the cardiovascular pathways, resulting in a reduction in systemic blood pressure.

How to use Vetranquil 1%?

The use of Vetranquil 1% (Acepromazine maleate) injection involves specific parameters regarding the route, dose calculation, timing, and professional supervision.

Administration Guidelines

Feature	Instruction Summary
Approved Routes	Intravenous (IV), Intramuscular (IM), or Subcutaneous (SC) injection.
Dosing Rule	Dosing is typically individualized based on the animal's body weight. The required dose per unit of weight generally decreases as the animal’s body weight increases.
Timing & Frequency	Administered as a single-use dose for an acute event or procedure. IV administration is performed slowly, and at least 15 minutes is allowed for the drug to take effect before proceeding.
Age-Group Rules	Smaller doses are generally indicated for very young and geriatric animals, as well as those in a debilitated state.
Supervision	The product is restricted to use by or on the order of a licensed veterinarian.

Resulting Procedural Structure

The protocol for using this injectable solution involves a sequence of specific steps. These steps involve administration via the approved parenteral routes, calculation based on weight, and proper timing before a procedure. This acute-use drug is not recommended for chronic or long-term administration. The administration is restricted to professional settings, as it is a veterinary prescription-only medication.

Evidence for Sedation and Chemical Restraint

The research landscape concerning the medicine was studied for tranquilization and chemical restraint through Randomized Controlled Trials (RCTs) and comparative clinical studies involving dogs, cats, and horses. Research explored outcomes like the degree of sedation using scoring scales and evaluating the patient's behavioral response to restraint. Studies reported measured changes in sedation scores shortly after administration, noting that these outcomes were consistently short-term, lasting several hours. Evidence is limited on the consistency of the measured effect when the patient experiences acute excitement, and the full extent of its role in long-term behavioral management is not well characterized.

Evidence for Pre-Anesthetic Support

The available research includes Controlled Interventional Studies and Randomized Comparative Trials that have explored the medicine was studied for use as a pre-anesthetic agent. Studies monitored outcomes such as the subsequent required dosage of the general anesthetic agent, anesthetic induction time, and quality of muscle relaxation. Findings described measured patterns related to a reduced requirement for general anesthetic agents in protocols where this compound was administered. Data are still emerging in comparison against the widest range of newer premedication protocols now available, and research exploring temporary physiological imbalance in patients with specific severe pre-existing health conditions remains limited.

Evidence for Symptomatic Relief

Research has explored its use for controlling vomiting associated with motion sickness and for supportive relief of itching outcomes linked to dermatitis. These studies include Controlled Clinical Trials and Investigator Reports, monitoring the measured incidence of vomiting and clinical assessments of patient comfort. Findings were mixed in some studies concerning the use for symptomatic relief, and the evidence base for itching relief relies largely on clinical observation. The volume of dedicated, large-scale controlled trials for these endpoints is lower, indicating that certainty remains low in these specific areas.

Evidence in Special Populations and Uncertainties

Research has explored the effects of the compound across different animal species, including dogs, cats, and horses, and certain studies have focused on specific genetic profiles of dogs. However, data for certain groups remain insufficient, particularly regarding patients with a wide variety of complex or severe comorbidities. Most available evidence is derived from studies focused on acute administration, meaning follow-up durations were limited and long-term outcomes are not fully established. Comparative evidence against the latest generation of alternative agents across all indications is often lacking in the current research literature.

Key Studies & References

1. NADA 016-566 Acepromazine Maleate Injectable (Vetranquil) - FDA Approved Label

Common questions about Vetranquil 1% (FAQ)

Q: Why is it important to check the eligibility criteria before using Vetranquil 1%?

Regulatory documents establish strict eligibility rules and contraindications for Vetranquil 1%. This is because the medicine is associated with risks, such as severe hypotension (low blood pressure), which can be intensified in high-risk patients. These criteria are set to limit the use of the medicine to patients who meet specified health standards, which helps to mitigate potential adverse outcomes.

Q: How long does it typically take for the effects of Vetranquil 1% to be noticeable according to research?

Official guidelines for administration state that, after the injection, at least 15 minutes should be allowed for the medicine to take its full effect before a procedure is initiated. This 15-minute timing is the period regulatory agencies indicate should be observed for proper administration.

Q: What is the expected duration of effect after using Vetranquil 1%?

The safety profile for Vetranquil 1% notes a prolonged duration of effect, meaning its potential influence can last an extended time. Research studies indicate that the primary measured outcomes are consistently short-term, typically lasting for several hours.

Q: Are there any common foods or drinks that regulatory documents warn against combining with Vetranquil 1%?

Regulatory information for the oral form of the active ingredient includes a pharmacokinetic note stating that antacids may cause a decrease in absorption. No common foods or drinks are specifically listed in the regulatory labeling for the injectable form. The documentation focuses on specific drug classes and components like antacids.

Q: Is there a maximum length of time described in official sources for using Vetranquil 1% continuously?

Official protocols describe Vetranquil 1% as a single-use dose intended for acute events and procedures, such as before surgery or during restraint. Regulatory documents explicitly state that the medicine is not recommended for chronic or long-term administration.

Q: Why do some people mention using Vetranquil 1% for things other than the main described use?

The official documentation only details the specific approved indications, which include sedation, chemical restraint, and pre-anesthetic support for approved species. Information regarding any other uses is not present in the regulatory labeling and is not detailed in the product’s official documentation.

Q: What is the general difference between Vetranquil 1% and non-prescription options?

Vetranquil 1% is restricted by Federal law to use by or on the order of a licensed veterinarian. This requires professional ordering and supervision, distinguishing it from non-prescription products that do not have such legal restrictions.

Q: What kind of studies have been performed on Vetranquil 1%?

Official regulatory summaries cite research performed across multiple formats to establish the medicine’s profile. The studies include formats such as Randomized Controlled Trials (RCTs), comparative clinical studies, Controlled Interventional Studies, and Investigator Reports.

Q: Is there clinical evidence supporting the described use of Vetranquil 1%?

Regulatory documents cite evidence that supports the approved uses for tranquilization, chemical restraint, and pre-anesthetic support. This evidence is based on measuring outcomes like sedation scoring scales and monitoring the reduced required dosage of subsequent general anesthetic agents.

Q: Can Vetranquil 1% cause changes in mood or behavior?

Vetranquil 1% is classified as a Central Nervous System (CNS) depressant. While its primary intended purpose is sedation, official regulatory documents report instances of paradoxical excitation or aggression, which are changes in behavior.

Q: Is it normal to feel a slight tingling sensation after using Vetranquil 1%?

A tingling sensation is not listed among the formally documented adverse reactions in the official regulatory documentation for Vetranquil 1%. Adverse reactions are typically detailed in the official patient information.

Q: Why are there different concentrations of similar medicines available, and what does the '1%' mean for Vetranquil?

The 1% designation for Vetranquil confirms the exact concentration of the active ingredient, Acepromazine maleate, in the injectable solution. Different concentrations are available to allow for variable delivery of the active ingredient, which may be needed across different species or patient profiles.

Q: Do any official documents recommend special monitoring while using Vetranquil 1%?

Official documentation advises caution for specific patient groups, such as those that are older or debilitated, due to their increased physiological sensitivity. This caution, along with dose reduction recommendations for certain patient profiles, indicates the need for careful professional supervision and monitoring.

Q: Does the efficacy of Vetranquil 1% change over time with continued use?

Research indicates that the drug’s effectiveness is limited when the patient is already experiencing acute excitement. Furthermore, evidence is limited regarding the drug’s use for long-term behavioral management, as most studies have focused on acute administration and long-term outcomes are not fully established.

Q: Is there information on the safety of Vetranquil 1% for very young animals (puppies/kittens)?

Official documents advise that smaller doses of Vetranquil 1% should be administered to very young (pediatric) patients, as well as geriatric patients. In some regions, there are specific contraindications prohibiting the use of this medicine in dogs less than three months of age.

Q: What happens if a patient uses Vetranquil 1% and it does not seem to provide the intended effect?

Official research evidence indicates that the drug’s effectiveness is limited when the patient is already experiencing acute excitement. For some non-core uses, the evidence base is lower, indicating less certainty about the expected effect in those specific situations.

Q: Are there differences in how Vetranquil 1% works in older adults compared to younger adults?

Official documents advise caution for older or debilitated patients due to their increased physiological sensitivity to the medicine. As a result, smaller doses are recommended for geriatric patients, which is an adjustment based on increased physiological sensitivity noted in official documents.

Q: How is the research on Vetranquil 1% currently being discussed in medical literature?

Regulatory documents note that research data are still emerging in comparison against the wider range of newer premedication protocols now available on the market. Additionally, studies exploring temporary physiological imbalance in patients with severe pre-existing health conditions remain limited in the current literature.

Q: Does Vetranquil 1% affect laboratory test results?

Yes, the regulatory label documents a potential effect on certain blood parameters. Specifically, a change in Packed Cell Volume (PCV) is documented as an adverse reaction that can occur due to splenic engorgement.

Q: Is there a possibility of an overdose with Vetranquil 1%?

The regulatory label describes clinical observations that occurred following the administration of dosages higher than recommended, indicating a theoretical risk associated with excessive amounts. Official documents advise consulting professional guidance if this occurs.

Q: What is the official definition of the condition Vetranquil 1% is approved to treat?

The medicine’s purpose, as stated in official documents, is the management of the behavioral state of agitation and anxiety, and it is used to support chemical restraint and controlled sedation. It is also officially approved for use as a pre-anesthetic agent.

How to Store and Dispose of Vetranquil 1%

Storage Conditions

Vetranquil 1% (acepromazine maleate) must be stored at a temperature not exceeding 25 C and must not freeze. To protect the solution from light, the vial must be kept in the outer carton as provided in the packaging. The medicinal product must be kept out of the sight and reach of children.

Stability After First Use

Once the vial is opened, the remaining solution has a defined stability period. The contents of the multi-dose container must be used within 28 days after the first dose is withdrawn. The product must be immediately discarded if any apparent growth or discolouration is observed in the solution.

Disposal Instructions

Disposal of unused or expired product must be managed responsibly. Medicines should not be disposed of via wastewater or household waste. Disposal must be carried out in accordance with guidance from the local waste regulation authority, utilizing national collection systems for veterinary medicinal products.